600,000 Bottles of Blood Pressure Drug Ramipril Recalled Over Contamination Risk
About 600,000 bottles of Ramipril, a common blood pressure medication, are being recalled across the U.S. due to contamination concerns linked to an unregulated supplier in India, the FDA announced. The recall affects 2.5 mg, 5 mg, and 10 mg doses distributed nationwide.
The FDA classified this as a Class 2 recall, meaning the contaminated product may cause temporary or medically reversible health problems, though serious adverse effects are unlikely. So far, no health issues have been reported. Patients are advised to check their prescriptions and consult healthcare providers if they believe their medication is part of the affected batches.
Ramipril is vital for managing hypertension and reducing risks of heart attacks, strokes, and kidney complications. Given its widespread use, the recall is causing concern among patients and doctors who depend on the drug for daily blood pressure control.
This recall also spotlights challenges in pharmaceutical supply chains, especially when ingredients come from overseas suppliers that may not meet strict U.S. regulatory standards. It emphasizes the need for better oversight and quality control.
Patients are urged not to stop taking Ramipril without medical advice but should immediately verify with their pharmacy or doctor whether their medication is impacted. Updated information and affected batch numbers are available through the FDA recall database or local pharmacies.
